The in vitro activities of delafloxacin and comparator antimicrobial agents against 6,485 bacterial isolates collected from medical centers in Europe and the United States in 2014 were tested. Delafloxacin was the most potent agent tested against methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant S. aureus, Streptococcus pneumoniae, viridans group streptococci, and beta-hemolytic streptococci and had activity similar to that of ciprofloxacin and levofloxacin against certain members of the Enterobacteriaceae. Overall, the broadest coverage of the tested pathogens (Gram-positive cocci and Gram-negative bacilli) was observed with meropenem and tigecycline in both Europe and the United States. Delafloxacin was shown to be active against organisms that may be encountered in acute bacterial skin and skin structure infections, respiratory infections, and urinary tract infections.
CITATION STYLE
Pfaller, M. A., Sader, H. S., Rhomberg, P. R., & Flamm, R. K. (2017). In vitro activity of delafloxacin against contemporary bacterial pathogens from the United States and Europe, 2014. Antimicrobial Agents and Chemotherapy, 61(4). https://doi.org/10.1128/AAC.02609-16
Mendeley helps you to discover research relevant for your work.